Stocks News

LAST PRICE
55.7100
TODAY'S CHANGE (%)
Trending Up2.3700 (4.4432%)

Bid / Lots
54.1400/ 2
Ask / Lots
59.8000/ 2
Open / Previous Close
54.0900 / 53.3400
Day Range
Low 53.8850
High 56.9300
52 Week Range
Low 19.8050
High 61.6100
Volume
632,889
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: MRUS
  09:06 AM EDT, 07/08/2024 (MT Newswires) -- Merus (MRUS) said Monday it has dosed first patient in its phase 2 trial of petosemtamab combined with standard chemotherapy to treat second-line metastatic colorectal cancer. The open-label trial aims to e...
- Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC, from 10 hours ago by GlobeNewswire
  10 hours ago by GlobeNewswire
  Companies Mentioned: MRUS
- Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: MRUS
  
  Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
  
  UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics(R) and Triclonics(R) ), today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in second line (2L) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics(R) targeting EGFR and LGR5.
Jul 1, 2024
- Sector Update: Health Care Stocks Retreat Late Afternoon, from 4:03PM ET on Monday Jul 01, 2024 by MT Newswires
  4:03PM ET on Monday Jul 01, 2024 by MT Newswires
  Companies Mentioned: COSM, TEVA, WBA, MRUS
  04:03 PM EDT, 07/01/2024 (MT Newswires) -- Health care stocks fell late Monday afternoon, with the NYSE Health Care Index 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.6%. The iShares Biotechnology ETF (IBB) eased 0.2%. I...
- Merus Names New Chief Medical Officer, from 12:43PM ET on Monday Jul 01, 2024 by MT Newswires
  12:43PM ET on Monday Jul 01, 2024 by MT Newswires
  Companies Mentioned: MRUS
  12:43 PM EDT, 07/01/2024 (MT Newswires) -- Merus (MRUS) said it has appointed Fabian Zohren as its chief medical officer, effective Monday. Zohren succeeds Andrew Joe, who will step down and continue as a consultant for the next three months, the co...

Jul 2, 2024
- DJ Crinetics Pharmaceuticals Is Maintained at Overweight by Piper Sandler, from 1:39PM ET on Tuesday Jul 02, 2024 by Dow Jones
  1:39PM ET on Tuesday Jul 02, 2024 by Dow Jones
  Companies Mentioned: CRNX
- Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints, from 10:36AM ET on Tuesday Jul 02, 2024 by MT Newswires
  10:36AM ET on Tuesday Jul 02, 2024 by MT Newswires
  Companies Mentioned: AMGN, ALVO
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R), from 9:00AM ET on Tuesday Jul 02, 2024 by GlobeNewswire
  9:00AM ET on Tuesday Jul 02, 2024 by GlobeNewswire
  Companies Mentioned: ALVO
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R), from 9:00AM ET on Tuesday Jul 02, 2024 by Dow Jones
  9:00AM ET on Tuesday Jul 02, 2024 by Dow Jones
  Companies Mentioned: ALVO
Jul 1, 2024
- Alvotech Issues New Shares to Holders of Convertible Bonds, from 5:35PM ET on Monday Jul 01, 2024 by GlobeNewswire
  5:35PM ET on Monday Jul 01, 2024 by GlobeNewswire
  Companies Mentioned: ALVO
- Alvotech Issues New Shares to Holders of Convertible Bonds, from 5:35PM ET on Monday Jul 01, 2024 by Dow Jones
  5:35PM ET on Monday Jul 01, 2024 by Dow Jones
  Companies Mentioned: ALVO
- Alvotech Reports Preliminary Q2 Revenue; Shares Rise Pre-Bell, from 6:25AM ET on Monday Jul 01, 2024 by MT Newswires
  6:25AM ET on Monday Jul 01, 2024 by MT Newswires
  Companies Mentioned: ALVO
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by GlobeNewswire
  5:10AM ET on Monday Jul 01, 2024 by GlobeNewswire
  Companies Mentioned: ALVO
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by Dow Jones
  5:10AM ET on Monday Jul 01, 2024 by Dow Jones
  Companies Mentioned: ALVO
- Press Release: Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by Dow Jones
  5:10AM ET on Monday Jul 01, 2024 by Dow Jones
  Companies Mentioned: ALVO

Merus NV
NASDAQ:MRUSUnited States

Search Criteria

Today

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate, from 9 hours ago by MT Newswires

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC, from 10 hours ago by GlobeNewswire

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC, from 10 hours ago by Dow Jones

Jul 1, 2024

Sector Update: Health Care Stocks Retreat Late Afternoon, from 4:03PM ET on Monday Jul 01, 2024 by MT Newswires

Merus Names New Chief Medical Officer, from 12:43PM ET on Monday Jul 01, 2024 by MT Newswires

Peers Headlines

Jul 2, 2024

DJ Crinetics Pharmaceuticals Is Maintained at Overweight by Piper Sandler, from 1:39PM ET on Tuesday Jul 02, 2024 by Dow Jones

Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints, from 10:36AM ET on Tuesday Jul 02, 2024 by MT Newswires

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R), from 9:00AM ET on Tuesday Jul 02, 2024 by GlobeNewswire

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R), from 9:00AM ET on Tuesday Jul 02, 2024 by Dow Jones

Jul 1, 2024

Alvotech Issues New Shares to Holders of Convertible Bonds, from 5:35PM ET on Monday Jul 01, 2024 by GlobeNewswire

Alvotech Issues New Shares to Holders of Convertible Bonds, from 5:35PM ET on Monday Jul 01, 2024 by Dow Jones

Alvotech Reports Preliminary Q2 Revenue; Shares Rise Pre-Bell, from 6:25AM ET on Monday Jul 01, 2024 by MT Newswires

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by GlobeNewswire

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by Dow Jones

Press Release: Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024, from 5:10AM ET on Monday Jul 01, 2024 by Dow Jones